Silence Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 159 K

Revenue: As of FY2025 Q3, the actual value is USD 159 K.

EPS: As of FY2025 Q3, the actual value is USD -0.15, missing the estimate of USD -0.148.

EBIT: As of FY2025 Q3, the actual value is USD -27.01 M.

Three months ended September 30, 2025: $0.2 million, a decrease of $1.3 million compared to the same period in 2024.
Nine months ended September 30, 2025: $0.5 million, a decrease of $17.4 million compared to the same period in 2024.

Three months ended September 30, 2025: - $0.06 million, a decrease of $3.6 million compared to the same period in 2024.
Nine months ended September 30, 2025: - $0.2 million, a decrease of $9.6 million compared to the same period in 2024.

Three months ended September 30, 2025: $0.1 million, an increase of $2.2 million compared to the same period in 2024.
Nine months ended September 30, 2025: $0.3 million, a decrease of $7.9 million compared to the same period in 2024.

Three months ended September 30, 2025: $20.5 million, an increase of $0.4 million compared to the same period in 2024.
Nine months ended September 30, 2025: $59.0 million, an increase of $13.2 million compared to the same period in 2024.

Three months ended September 30, 2025: $5.8 million, a decrease of $1.9 million compared to the same period in 2024.
Nine months ended September 30, 2025: $18.6 million, a decrease of $2.7 million compared to the same period in 2024.

Three months ended September 30, 2025: - $26.2 million, a decrease of $3.8 million compared to the same period in 2024.
Nine months ended September 30, 2025: - $78.6 million, an increase of $19.6 million compared to the same period in 2024.

Three months ended September 30, 2025: $1.9 million, an increase of $13.3 million compared to the same period in 2024.
Nine months ended September 30, 2025: - $8.4 million, an increase of $2.8 million compared to the same period in 2024.

Three months ended September 30, 2025: $0.8 million, a decrease of $0.6 million compared to the same period in 2024.
Nine months ended September 30, 2025: $2.6 million, a decrease of $0.8 million compared to the same period in 2024.

Three months ended September 30, 2025: $2.6 million, a decrease of $1.9 million compared to the same period in 2024.
Nine months ended September 30, 2025: $7.6 million, a decrease of $2.1 million compared to the same period in 2024.

Three months ended September 30, 2025: - $21.0 million, a decrease of $14.6 million compared to the same period in 2024.
Nine months ended September 30, 2025: - $76.8 million, an increase of $19.2 million compared to the same period in 2024.

Net cash outflow from operating activities: - $45.0 million for the nine months ended September 30, 2025, an increase of $4.8 million compared to the same period in 2024.
Net cash inflow from investing activities: $5.3 million for the nine months ended September 30, 2025, compared to - $88.1 million in the same period in 2024.
Net cash inflow from financing activities: $0.0 million for the nine months ended September 30, 2025, compared to $142.2 million in the same period in 2024.

Core Business Focus: Silence Therapeutics plc plans to continue its research and development efforts, focusing on advancing its proprietary siRNA product candidates, including divesiran and zerlasiran, through clinical trials. The company aims to achieve regulatory approvals and commercialize these products, targeting significant unmet medical needs in cardiovascular disease, hematology, and rare diseases.
Non-Core Business: The company will also explore potential collaborations and partnerships to support the development and commercialization of its product candidates. Silence Therapeutics plc is committed to maximizing its mRNAi GOLD platform by advancing both wholly owned and partnered programs.
Priority: The company aims to achieve key milestones, including the announcement of initial topline results from the SANRECO Phase 2 clinical trial for divesiran in the third quarter of 2026 and seeking a third-party partner for Phase 3 development of zerlasiran.